Answers are grounded in this paper and cite their sources.
Ferroptosis, a form of cell death induced by overwhelming membrane lipid peroxidation, is a vulnerability of many cancers, including cancers resistant to current molecular and immune-based therapies 1–7 . Triggering of ferroptosis therefore provides an opportunity to achieve elimination of difficult-to-treat cancers 1–4,8,9 . Studies in mouse cancer models have demonstrated that anticancer immunity, mediated by dendritic cells (DCs) and CD8 + T cells, is essential for effective tumour eradication by ferroptosis-inducing strategies 10–13 . However, ferroptotic cells limit this response 8–10,14 , resulting in immune escape and tumour growth through mechanisms that remain unclear. Here we demonstrate that ferroptotic cancer cells activate a molecular program resulting in aberrant production of prostaglandin E 2 (PGE 2 ), which limits the stimulation of anticancer CD8 + T cell responses by type 1 conventional DCs (cDC1s), thereby promoting immune escape. In ferroptotic cancer cells, lipid peroxidation-mediated membrane permeabilization enables Ca 2+ influx, which activates p38 MAPK signalling and thereby drives PGE 2 production. This signalling axis is uncoupled from cancer cell death and can be targeted to selectively interfere with immune-inhibitory PGE 2 production while preserving ferroptotic cancer cell elimination. In the context of cancer cell ferroptosis, ablation of PGE 2 production or disrupting PGE 2 signalling restores cDC1-mediated anticancer CD8 + T cell responses and leads to effective tumour elimination. Our findings identify a key mechanism that limits antitumour immunity and prevents tumour elimination upon ferroptosis induction in cancer cells, which could be exploited for cancer therapy.
No takes yet. Share an insight, caveat, or question.
Ramsauer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: